SOUTH SAN FRANCISCO—Novacea, a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies, has named biotechnology public relations veteran Paul Laland vice president of corporate communications. Laland joins Novacea from VaxGen, another biopharmaceutical company, where he served as vice president of public affairs.
Laland will be responsible for strategic communications efforts that support Novacea’s oncology franchise and corporate business goals, including the company’s lead product candidate, DN-101, currently in a Phase 3 clinical trial for advanced prostate cancer. He will also direct the company’s public relations and financial communications activities.
Prior to VaxGen, Laland served as senior partner and co-chair of the global healthcare practice at Fleishman-Hillard. He has also served in various corporate communications positions at Genentech, Synergen, G.D. Searle and Deltagen.